- Y Diweddaraf sydd Ar Gael (Diwygiedig)
- Gwreiddiol (a wnaed Fel)
Dyma’r fersiwn wreiddiol (fel y’i gwnaed yn wreiddiol). This item of legislation is currently only available in its original format.
2. In Schedule 1 to the principal Order (which specifies substances which if included in medicinal products make those products prescription only medicines and exemptions from restrictions on the sale and supply of prescription only medicines)—
(a)in relation to the substance Aspirin(1), the entries in columns 2, 3 and 5 numbered “(1)” are re-numbered “(2)”, the entry in column 3 numbered “(2)” is re-numbered “(3)”; and, before those entries re-numbered “(2)”, there are inserted the following entries—
in column 2—
“(1) 75mg”,
in column 3—
“(1) Non-effervescent tablets and capsules”,
in column 5—
“(1) The quantity sold or supplied in one container or package shall not exceed 100
The quantity of non-effervescent tablets, capsules or a combination of both sold or supplied to a person at any one time shall not exceed 100”;
(b)in relation to the substance Beclomethasone Dipropionate(2), in the entry in column 5, for “5,600 mcg” there is substituted “20,000 mcg”;
(c)in relation to the substance Hydrocortisone(3), the entry in each of columns 2 and 5 is, and the entries in column 3 are, numbered “(2)”; and, before the entries in columns 2, 3 and 5, there are inserted the following entries—
in column 2—
“(1) 0.5 per cent”,
in column 3—
“(1) External
For use in combination with Nystatin of maximum strength 3.0 per cent for intertrigo
For use in adults and children not less than 10 years”,
in column 5—
“(1) Container or package containing not more than 15g of medicinal product”;
(d)in relation to the substance Nystatin, there are inserted the following entries—
in column 2—
“3.0 per cent”,
in column 3—
For use in combination with Hydrocortisone of maximum strength 0.5 per cent for intertrigo
For use in adults and children not less than 10 years”,
in column 5—
“Container or package containing not more than 15g of medicinal product”; and
(e)there is inserted in column 1, at the appropriate place in the alphabetical order of the entries in that column, each of the following substances—
“Candesartan Cilexetil”
“Lornoxicam”
“Losartan Potassium”
“Nebivolol Hydrochloride”
“Nisoldipine”
“Propiverine Hydrochloride”
“Quetiapine Fumarate”
“Tacalcitol Monohydrate”.
Y Diweddaraf sydd Ar Gael (diwygiedig):Y fersiwn ddiweddaraf sydd ar gael o’r ddeddfwriaeth yn cynnwys newidiadau a wnaed gan ddeddfwriaeth ddilynol ac wedi eu gweithredu gan ein tîm golygyddol. Gellir gweld y newidiadau nad ydym wedi eu gweithredu i’r testun eto yn yr ardal ‘Newidiadau i Ddeddfwriaeth’.
Gwreiddiol (Fel y’i Deddfwyd neu y’i Gwnaed): Mae'r wreiddiol fersiwn y ddeddfwriaeth fel ag yr oedd pan gafodd ei deddfu neu eu gwneud. Ni wnaed unrhyw newidiadau i’r testun.
Gallwch wneud defnydd o ddogfennau atodol hanfodol a gwybodaeth ar gyfer yr eitem ddeddfwriaeth o’r tab hwn. Yn ddibynnol ar yr eitem ddeddfwriaeth sydd i’w gweld, gallai hyn gynnwys: